Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · mng-umap@100

MNG914

—

26fbf2b2-ea7b-5b65-b76d-996c8bdac3d0

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • INTERFERON_ALPHA_RESPONSE+0.619
  • INTERFERON_GAMMA_RESPONSE+0.494
  • E2F_TARGETS+0.410
  • G2M_CHECKPOINT+0.382
  • DNA_REPAIR+0.337
  • MYC_TARGETS_V1+0.334
  • ALLOGRAFT_REJECTION+0.285
  • MYC_TARGETS_V2+0.281
  • OXIDATIVE_PHOSPHORYLATION+0.252
  • CHOLESTEROL_HOMEOSTASIS+0.250

Top 10 suppressed

  • TGF_BETA_SIGNALING-0.327
  • PANCREAS_BETA_CELLS-0.289
  • ANDROGEN_RESPONSE-0.281
  • COAGULATION-0.269
  • HEME_METABOLISM-0.244
  • HEDGEHOG_SIGNALING-0.212
  • ESTROGEN_RESPONSE_LATE-0.199
  • ESTROGEN_RESPONSE_EARLY-0.191
  • HYPOXIA-0.191
  • EPITHELIAL_MESENCHYMAL_TRANSITION-0.169

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

10 twins match this tumor's tissue · 0 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1TCGA-CV-A6JZ-01A-11R-A31N-07
head-neck@1
——0.837
2SRR8518289
breast-umap@18
—E0.825
3SRR8518360
breast-umap@18
—E0.805
4MNG277
mng-umap@100
——0.795
5TCGA-18-3416-01A-01R-0980-07
lung-landscapes@6
—cohortSQ20.793
6TCGA-T3-A92N-01A-11R-A39I-07
head-neck@1
——0.792
7TCGA-HD-7832-01A-11R-2132-07
head-neck@1
——0.790
8MNG171
mng-umap@100
——0.789
9MNG95
mng-umap@100
——0.787
10TCGA-AR-A0TU-01A-31R-A109-07
breast-umap@18
—E0.786

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 23 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
INTERFERON_ALPHA_RESPONSE0.619Inavolisib— uncovered
INTERFERON_GAMMA_RESPONSE0.494Idelalisib— uncovered
E2F_TARGETS0.410Inavolisib— uncovered
G2M_CHECKPOINT0.382Inavolisib— uncovered
DNA_REPAIR0.337Idelalisib— uncovered
MYC_TARGETS_V10.334Inavolisib— uncovered
ALLOGRAFT_REJECTION0.285Idelalisib— uncovered
MYC_TARGETS_V20.281Idelalisib— uncovered
OXIDATIVE_PHOSPHORYLATION0.252Remibrutinib— uncovered
CHOLESTEROL_HOMEOSTASIS0.250Remibrutinib— uncovered
MTORC1_SIGNALING0.185Inavolisib— uncovered
UNFOLDED_PROTEIN_RESPONSE0.157Idelalisib— uncovered
FATTY_ACID_METABOLISM0.110Inavolisib— uncovered
ADIPOGENESIS0.081Inavolisib— uncovered
PI3K_AKT_MTOR_SIGNALING0.077Inavolisib— uncovered
MITOTIC_SPINDLE0.065Inavolisib— uncovered
PEROXISOME0.054Idelalisib— uncovered
SPERMATOGENESIS0.049Inavolisib— uncovered
APICAL_SURFACE0.039Temsirolimus— uncovered
IL6_JAK_STAT3_SIGNALING0.023Inavolisib— uncovered